Biweekly TPF Regimen Doses
For a biweekly (2-weekly) TPF regimen, the recommended doses are: docetaxel 40 mg/m², cisplatin 40 mg/m² (or carboplatin AUC2), folinic acid 400 mg/m², 5-FU 400 mg/m² bolus followed by 1,000 mg/m²/day continuous infusion over 46 hours, administered every 14 days.
Evidence Basis
The biweekly TPF regimen represents a dose-dense modification of the standard 3-weekly TPF protocol. While standard TPF guidelines recommend 3-weekly dosing 1, 2, the dose-dense approach has been specifically studied and validated.
Standard 3-Weekly TPF Dosing (For Context)
The established 3-weekly regimens use:
- Docetaxel: 60-75 mg/m² day 1 1
- Cisplatin: 60-75 mg/m² day 1 1
- 5-FU: 600-750 mg/m²/day continuous infusion days 1-5 1
FDA labeling confirms docetaxel 75 mg/m² with cisplatin 75 mg/m² and 5-FU 750 mg/m²/day for 5 days every 3 weeks for head and neck cancer 2.
Biweekly Dose-Dense Modification
The validated biweekly regimen uses approximately 50% dose reduction per cycle but doubles the frequency 3:
- Docetaxel: 40 mg/m² day 1
- Cisplatin: 40 mg/m² day 1 (carboplatin AUC2 is an alternative)
- Folinic acid: 400 mg/m² over 2 hours
- 5-FU: 400 mg/m² bolus followed by 1,000 mg/m²/day continuous infusion over 46 hours
- Cycle frequency: Every 14 days
Safety and Efficacy Profile
The biweekly regimen demonstrated 3:
- No intestinal toxicity in 68% of patients
- Grade 3-4 hematological toxicity in only 13.5%
- Objective response rate of 54.5% overall (90% for induction, 39% for palliative)
- Requires G-CSF primary prophylaxis in most patients (81%)
This compares favorably to standard 3-weekly TPF, which shows grade 3-4 neutropenia in 35%, leukopenia in 27%, and diarrhea in 8% 1.
Clinical Implementation
Key modifications from standard TPF:
- Reduce individual drug doses by approximately 50%
- Administer every 2 weeks instead of 3 weeks
- Use modified 5-FU schedule (De Gramont-style with folinic acid and shorter infusion)
- Implement G-CSF prophylaxis routinely
Important caveats:
- This regimen has been studied primarily in head and neck cancers 3
- For elderly patients (≥65 years), consider 30% dose reduction from the biweekly doses
- Monitor closely for cumulative toxicity despite lower per-cycle doses
- The dose-dense approach maintains dose intensity while potentially improving tolerability
The biweekly schedule offers comparable efficacy to standard 3-weekly TPF with potentially improved gastrointestinal tolerability, though it requires more frequent administration and routine growth factor support 3.